List of Excipients in Branded Drug ENTADFI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Veru Inc	ENTADFI	finasteride and tadalafil	69681-125	CARRAGEENAN
Veru Inc	ENTADFI	finasteride and tadalafil	69681-125	CELLULOSE, MICROCRYSTALLINE
Veru Inc	ENTADFI	finasteride and tadalafil	69681-125	HYPROMELLOSE

ENTADFI Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

ENTADFI is a fixed-dose oral capsule containing tadalafil 5 mg and finasteride 5 mg for initiating treatment of urinary symptoms associated with benign prostatic hyperplasia in men with an enlarged prostate. Its commercial opportunity is concentrated in formulation differentiation, generic substitution, excipient-risk management, and lifecycle products that improve tolerability, manufacturing efficiency, or patient convenience. The principal development constraint is that tadalafil and finasteride have different physicochemical and regulatory profiles, so a successful alternative must demonstrate bioequivalence for both active ingredients without changing the product’s clinical use profile.

What is ENTADFI and how is it formulated?

ENTADFI combines two established active pharmaceutical ingredients:

Attribute	ENTADFI profile
Active ingredients	Tadalafil 5 mg and finasteride 5 mg
Dosage form	Oral capsule
Therapeutic area	Benign prostatic hyperplasia
FDA application	NDA 214963
Sponsor	Veru Inc.
FDA approval	December 2021
Recommended use	Once daily for treatment initiation, up to 26 weeks
Regulatory pathway	New drug application
Primary commercial rationale	Single-capsule initiation therapy combining rapid symptom relief with prostate-volume reduction

Tadalafil is a phosphodiesterase type 5 inhibitor. Finasteride is a 5-alpha-reductase inhibitor. The combination addresses different components of BPH management: tadalafil can improve lower urinary tract symptoms, while finasteride reduces dihydrotestosterone-driven prostate enlargement over time.

The FDA prescribing information identifies the product as a capsule containing both active ingredients and a set of conventional pharmaceutical excipients. The capsule platform must support dose uniformity, dissolution, chemical stability, and manufacturability for two APIs with different dose-to-weight ratios and different formulation histories.[1]

What excipients are used in ENTADFI?

ENTADFI’s inactive ingredients include conventional capsule-fill and capsule-shell materials. Public product information identifies excipients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, sodium lauryl sulfate, and magnesium stearate. The capsule shell contains gelatin and colorants, including titanium dioxide and blue coloring components.[1,2]

Excipient function	Likely ENTADFI role	Commercial relevance
Lactose monohydrate	Diluent and carrier	Low cost, established supply chain, but creates lactose and animal-origin positioning issues
Microcrystalline cellulose	Filler and compression or granulation aid	Supports blend uniformity and capsule-fill consistency
Croscarmellose sodium	Disintegrant	Supports capsule-fill breakup and dissolution
Hydroxypropyl cellulose	Binder or matrix-support excipient	Improves granule or blend cohesion
Sodium lauryl sulfate	Wetting or dissolution aid	Can improve drug wetting but raises tolerability and formulation-perception concerns
Magnesium stearate	Lubricant	Supports processing but can affect dissolution if over-lubrication occurs
Gelatin	Capsule shell	Standard hard-capsule material, but creates vegetarian and religious-compliance limitations
Titanium dioxide and colorants	Capsule appearance and identification	Relevant to market-specific formulation and colorant restrictions

The exact quantitative composition, manufacturing process, particle-size distribution, and order of addition are not fully disclosed in the public prescribing information. Those parameters may be more important than the excipient names themselves when assessing freedom to operate or designing an equivalent product.

How can an excipient strategy improve ENTADFI?

The strongest opportunity is not a simple excipient substitution. It is a controlled reformulation strategy that preserves the pharmacokinetic profile of tadalafil and finasteride while improving manufacturability, patient acceptability, or market access.

1. Lactose-free formulation

A lactose-free capsule could target patients who avoid lactose or manufacturers seeking a simplified excipient statement. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or selected starch-based fillers could replace lactose.

The principal risks are changes in:

• Bulk density and capsule fill weight
• Blend segregation
• Moisture exposure
• Dissolution behavior
• Content uniformity for the lower-mass component
• Supplier qualification and global regulatory acceptability

A lactose-free formulation would have the clearest commercial value in markets where excipient labeling materially affects prescribing or pharmacy substitution.

2. Vegetarian or HPMC capsule shell

Replacing gelatin with a hydroxypropyl methylcellulose capsule could create a vegetarian, vegan-compatible, or non-animal-origin product. HPMC shells also can offer different moisture behavior and reduced dependence on animal-derived supply chains.

The change would require comparative evaluation of:

• Shell moisture content
• Capsule brittleness
• Tadalafil and finasteride stability
• Dissolution under relevant pH conditions
• Packaging performance
• Appearance and identification

The commercial advantage is strongest for multinational distribution, institutional procurement, and markets with religious or dietary restrictions. The regulatory burden may be manageable if the formulation remains bioequivalent and the capsule-shell change does not alter release.

3. Sodium-lauryl-sulfate reduction or removal

Sodium lauryl sulfate can improve wetting and dissolution, but it may be viewed negatively by some patients and formulators. A development program could evaluate lower levels or alternative wetting systems, including poloxamers, sodium docusate, or surfactant-free particle-engineering approaches.

The risk is that tadalafil and finasteride may not respond identically to the same wetting system. Removing the surfactant could produce slower dissolution or greater batch-to-batch variability. Any substitution should be assessed through comparative dissolution, stability, and bioequivalence work rather than excipient-function assumptions.

4. Improved blend uniformity

ENTADFI contains equal nominal masses of tadalafil and finasteride, but equal dose does not guarantee equal blending behavior. Differences in particle size, morphology, density, electrostatic properties, and surface area can cause segregation.

A higher-value manufacturing strategy could use:

• Co-milling or particle-size harmonization
• Ordered mixing
• Wet granulation
• Dry granulation
• Spray-dried API-excipient composites
• Separate API granules filled into one capsule
• Quantitative process analytical technology

The opportunity is particularly relevant for contract manufacturers and generic developers seeking to reduce content-uniformity failures and improve yield.

What formulations are protected by ENTADFI-related intellectual property?

The commercial product is potentially protected by patents covering the fixed-dose combination, treatment methods, dosage regimens, and formulation architecture. Patent scope should be separated into four categories:

Patent category	Potential subject matter	Competitive effect
Composition patents	Tadalafil-finasteride combinations and strength ratios	Can delay directly substitutable fixed-dose products
Method-of-use patents	Use of the combination for BPH symptoms or treatment initiation	May create method-of-use litigation risk
Formulation patents	Capsule composition, excipient system, dissolution control, or stability	Can restrict excipient-engineered copies
Manufacturing patents	Granulation, blending, encapsulation, or process controls	May create process-design constraints

A formulation competitor does not necessarily infringe a composition patent merely because it uses the same active ingredients. Conversely, changing excipients does not avoid infringement if a patent claim covers the active combination or a broad dosage form.

Patent analysis should review the issued claims, terminal disclaimers, patent-term adjustment, Orange Book listings, prosecution history, and continuation applications. The public FDA label confirms the approved NDA and product composition at a high level, but the label is not a complete patent-rights record.[1]

What is the Orange Book status of ENTADFI?

ENTADFI is an FDA-approved prescription drug marketed under NDA 214963. The FDA Orange Book is the controlling public source for listed patents and exclusivity associated with an approved small-molecule product.[3]

Key regulatory points are:

• ENTADFI is a small-molecule product, not a biologic.
• Biosimilar pathways do not apply.
• A competing fixed-dose product would generally be evaluated through an abbreviated new drug application if it can satisfy applicable sameness and bioequivalence requirements.
• Patent certification strategy would depend on the patents listed for the reference product when the ANDA is filed.
• Method-of-use patents may require a section viii statement or a carve-out if the FDA-approved labeling permits a legally viable non-infringing indication.

Current Orange Book patent status should be determined from the live FDA listing and related patent records. Patent expiration cannot be inferred reliably from the approval date alone because listed patents may have different priority dates, patent-term adjustments, terminal disclaimers, or pediatric extensions.

When does ENTADFI lose exclusivity?

ENTADFI’s FDA approval date was December 2021. FDA regulatory exclusivity and patent exclusivity are separate.

For an NDA product approved with new clinical information, five-year new chemical entity exclusivity may not apply in the same way as it would for a product containing a new active moiety, because tadalafil and finasteride were previously approved active ingredients. The product may instead rely on patent protection, clinical-investigation exclusivity, listed method-of-use rights, or other product-specific protections.

The commercially relevant entry date depends on:

1. The active Orange Book patent listings.
2. The earliest valid ANDA filing date.
3. Paragraph IV certifications.
4. Litigation filed within the statutory period.
5. Any 30-month stay.
6. Settlement terms.
7. The scope of any labeling carve-out.
8. Whether the generic applicant seeks a capsule with the same active ingredients or a different presentation.

A definitive launch calendar requires a live review of FDA exclusivity records, Orange Book listings, USPTO patent data, and federal court dockets.

Which companies are challenging ENTADFI?

ENTADFI competes with the individual products tadalafil and finasteride, including generic versions of both medicines. The most direct future challenge would come from an ANDA applicant seeking approval for a fixed-dose tadalafil-finasteride capsule.

The competitive field includes:

• Generic tadalafil manufacturers
• Generic finasteride manufacturers
• Combination-product developers
• Contract development and manufacturing organizations
• Specialty pharmaceutical companies pursuing BPH lifecycle products
• Firms developing alternative capsule shells or excipient systems

Separate tadalafil and finasteride products already provide a practical substitute for physicians and patients. That substitution limits the commercial moat of a fixed-dose combination unless ENTADFI demonstrates better adherence, lower dispensing friction, or a meaningful treatment-initiation advantage.

What generic entry risks exist for ENTADFI?

The generic opportunity is technically feasible but not frictionless.

Bioequivalence complexity

An ANDA applicant must demonstrate bioequivalence for both tadalafil and finasteride. The study design must account for:

• Two active ingredients
• Potential differences in absorption rates
• Fed and fasted conditions
• Inter-individual variability
• Capsule-fill segregation
• Dissolution across multiple media
• Stability of both APIs in the same package

A formulation that matches the label’s excipient list may still fail bioequivalence if the manufacturing process changes drug release or absorption.

Patent-certification risk

A paragraph IV challenge could trigger patent litigation and a statutory stay. The challenger would need a credible non-infringement or invalidity position. Formulation patents may be vulnerable to prior-art challenges if their claims are narrow and predictable, while broader combination or method claims may present a larger litigation burden.

Labeling constraints

Finasteride carries handling warnings for pregnant women and risks relating to sexual adverse effects. Tadalafil carries contraindications and warnings involving nitrates, alpha-blockers, blood-pressure effects, and cardiovascular conditions.[1] An ANDA must reproduce required labeling, subject to permitted carve-outs.

How strong is the ENTADFI patent estate?

The patent estate’s practical strength depends more on claim breadth and remaining term than on the number of patent families.

Strength factor	Assessment
Active ingredients	Weak barrier because tadalafil and finasteride are individually established
Fixed-dose combination	Potentially meaningful if claims cover broad ratios or treatment methods
Capsule formulation	Potentially avoidable through excipient and process redesign
Method of use	Dependent on claim language and labeling carve-out feasibility
Manufacturing process	Usually avoidable if alternative processing achieves equivalent performance
Regulatory exclusivity	Likely less durable than patent protection for an established-ingredient combination
Biosimilar protection	Not applicable

The estate is therefore likely to be stronger against an exact-copy fixed-dose capsule than against a carefully engineered alternative with different excipients, process conditions, or labeling strategy. That conclusion is technical and commercial, not a legal infringement opinion.

What commercial opportunities exist for excipient suppliers and developers?

Excipient suppliers

Suppliers can target ENTADFI-related development through:

• Direct-compression lactose alternatives
• Low-moisture microcrystalline cellulose
• Co-processed fillers
• Novel disintegrants
• HPMC capsule shells
• Low-peroxide excipient grades
• Surfactant alternatives
• Functional excipients that improve dissolution without sodium lauryl sulfate

Supplier value increases when the excipient reduces process complexity or supports a defensible formulation patent.

Generic manufacturers

A generic developer could differentiate through:

• Lactose-free composition
• Vegetarian capsule shell
• Reduced surfactant load
• Improved capsule-filling yield
• Smaller capsule size
• Calendar packaging for treatment initiation
• Global excipient harmonization
• Alternative manufacturing that avoids potentially claimed processes

The best target is a formulation that lowers cost and reduces excipient restrictions without introducing a new clinical study burden.

Brand or specialty-license opportunities

A branded lifecycle product could pursue:

• A capsule with a vegetarian shell
• A patient-friendly blister pack
• A formulation optimized for patients with swallowing difficulty
• A co-packaged initiation regimen
• A fixed-dose capsule with differentiated excipient tolerability
• A regional licensing strategy built around manufacturing rights

Each opportunity must be measured against the limited treatment duration in the approved label. A 26-week initiation product may have lower willingness-to-pay than a chronic-use formulation unless it produces measurable adherence or prescribing benefits.

How does ENTADFI compare with separate tadalafil and finasteride products?

Factor	ENTADFI	Separate products
Dosing burden	One capsule	Two products or dosage forms
Flexibility	Fixed 5 mg/5 mg doses	Independent dose adjustment
Formulation differentiation	Limited to one combination product	Broad product and manufacturer choice
Pharmacy substitution	Depends on combination-product availability	Extensive generic availability
Adherence potential	May reduce pill burden	More complex regimen
Clinical positioning	Treatment initiation for BPH	Independent indication and dose decisions
Commercial barrier	Combination-product patents and bioequivalence	Mature generic competition
Excipient control	Single fixed composition	Greater ability to select separate products

The combination has a convenience advantage, but separate products provide more dosing flexibility and are typically less exposed to fixed-dose product availability. ENTADFI’s commercial position depends on whether prescribers value single-capsule initiation enough to overcome the price and substitution advantages of generics.

What FDA regulatory issues affect ENTADFI excipient reformulation?

A material excipient change may require a new regulatory filing, depending on whether the product is the reference drug, an approved generic, or a reformulated branded product.

Key regulatory considerations include:

• Comparative dissolution
• Assay and content uniformity
• Impurity and degradation profiles
• Capsule-shell compatibility
• Stability under ICH conditions
• Food-effect assessment where required
• Pharmacokinetic bioequivalence
• Labeling changes
• Container-closure qualification
• Excipient precedent and maximum daily exposure

For an ANDA, the product must generally match the reference product in active ingredients, dosage form, route, strength, and performance characteristics, subject to FDA requirements. For a new branded formulation, the sponsor may have more latitude but faces a more extensive clinical and regulatory program.

Key Takeaways

• ENTADFI is a tadalafil 5 mg and finasteride 5 mg fixed-dose capsule approved for BPH treatment initiation.
• Its main excipient opportunities are lactose removal, HPMC capsule shells, surfactant optimization, and improved blend uniformity.
• Excipients can create commercial differentiation, but they do not automatically avoid composition or method-of-use patents.
• ENTADFI is a small-molecule product; biosimilar risk does not apply.
• Generic entry is likely to focus on ANDA bioequivalence, patent certifications, and formulation design-around strategies.
• Separate generic tadalafil and finasteride products are the principal commercial substitutes.
• The product’s limited treatment-initiation duration may constrain pricing and revenue potential.
• A definitive exclusivity and launch analysis requires the current Orange Book listing, patent claims, prosecution history, and litigation docket.

FAQs About ENTADFI Excipient and Commercial Strategy

Can ENTADFI be reformulated as a tablet?

Yes. A tablet containing tadalafil and finasteride could be developed, but it would not automatically qualify as an equivalent product. The sponsor would need to address dissolution, bioequivalence, stability, dose uniformity, and any patent claims covering the capsule or combination.

Is ENTADFI suitable for a lactose-intolerant patient?

The marketed formulation contains lactose monohydrate according to public product information. A lactose-free alternative would require a different approved formulation or a separately manufactured product.

Can a generic ENTADFI use different excipients?

Potentially. Generic products can use different inactive ingredients when they satisfy FDA requirements for safety, performance, bioequivalence, and labeling. The changes must also be assessed against formulation and process patent claims.

Does ENTADFI have biosimilar competition?

No. Tadalafil and finasteride are small-molecule active ingredients. Competitive products would use generic-drug pathways rather than the biosimilar pathway.

What is the highest-value excipient opportunity for ENTADFI?

A co-processed, lactose-free filler-disintegrant system combined with a vegetarian HPMC capsule is the clearest commercial concept. It could address excipient restrictions, simplify global positioning, and support manufacturing differentiation if bioequivalence and stability are maintained.

References

1. U.S. Food and Drug Administration. (2021). ENTADFI (tadalafil and finasteride) capsules, prescribing information. FDA.
2. National Library of Medicine. (n.d.). ENTADFI- tadalafil and finasteride capsule. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2022). ANDA product-specific guidance and bioequivalence recommendations for oral dosage forms. FDA.